Evaluation of Outcomes in Patients With Carcinoma of the Cervix Treated With Concurrent Radiation and Cisplatin Versus Cisplatin/5-FU Compared With Radiation Alone

Donnelly, Eric D.; Refaat, Tamer; Gentile, Michelle S.; Herskovic, Alex; Boyle, John; Helenowski, Irene; Rademaker, Alfred; Lurain, John R.; Schink, Julian C.; Singh, Diljeet K.; Strauss, Jonathan B.; Small, William

doi:10.1097/coc.0b013e3182a1b448

Cited by 13 publications

(5 citation statements)

References 18 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study included 17 literature with 4,106 patients, while the literature consisted of 5 retrospective studies [ 10 – 14 ] and 12 prospective studies [ 4 , 8 , 15 – 24 ]. Among them, 2,066 patients received platinum-based dual drug therapy combining CCRT, while 2,040 patients received platinum monotherapy combining CCRT.…”

Section: Resultsmentioning

confidence: 99%

Comparison of platinum monotherapy with concurrent chemoradiation therapy versus platinum-based dual drug therapy with concurrent chemoradiation therapy for locally advanced cervical cancer: a systematic review and meta-analysis

Deng

et al. 2022

Infect Agents Cancer

View full text Add to dashboard Cite

Objective To compare the survival outcomes and adverse events of patients with locally advanced cervical cancer (LACC) who received platinum monotherapy with concurrent chemoradiation therapy (CCRT) versus platinum-based dual drug therapy with CCRT. Method All relevant literature was screened form the PubMed, EMBASE, Web of Science, The Cochrane Library and other databases from their establishment to October 2020. The main endpoint indicators included overall survival (OS) and progression-free survival (PFS). Grade 3 and above adverse events induced by chemotherapy were also compared. Results This study involved 17 literature and 4,106 patients. There were 2,066 patients treated with CCRT with platinum-based dual drug therapy and 2,040 patients received CCRT with platinum monotherapy. Meta-analysis results showed that, compared to CCRT with platinum monotherapy, OS (HR = 0.68, 95% CI 0.58–0.79) and PFS (HR = 0.67, 95% CI 0.58–0.77) of LACC patients were significantly improved by CCRT with platinum-based dual drug therapy. In addition, CCRT with platinum-based dual drug therapy led to more adverse reactions such as neutropenia (OR = 4.92, 95% CI 3.55–6.84), anemia (OR = 1.99, 95% CI 1.17–3.39), diarrhea (OR = 1.70, 95% CI 1.30–2.22), leukopenia (OR = 2.42, 95%CI 1.84–3.17), thrombocytopenia (OR = 2.87, 95%CI 1.44–5.72), etc. Conclusion CCRT with platinum-based dual drug therapy improved OS and PFS of LACC patients relative to the CCRT with platinum monotherapy. But it also increased the adverse reactions caused by multiple chemotherapy drugs. Thus, it is crucial to select a proper chemotherapy regimen based on the actual tolerance of patients in clinical practice.

show abstract

Section: Resultsmentioning

confidence: 99%

Comparison of platinum monotherapy with concurrent chemoradiation therapy versus platinum-based dual drug therapy with concurrent chemoradiation therapy for locally advanced cervical cancer: a systematic review and meta-analysis

Deng

et al. 2022

Infect Agents Cancer

View full text Add to dashboard Cite

show abstract

“…In fact, some of the most powerful predictors of patient outcomes are not particular laboratory values but comprehensive and integrative assessments such as the performance status, a measure of a patient's overall well-being through combined quantitative (test values) and qualitative observations (physical examination). 16…”

Section: Clinical Judgment: the Original Similarity-based Approachmentioning

confidence: 99%

Opportunities for Patient Matching Algorithms to Improve Patient Care in Oncology

Johnson

Liebner

Chen

2017

JCO Clinical Cancer Informatics

View full text Add to dashboard Cite

show abstract

“…3,4 According to various studies, Capecitabine has shown promising results as a radio sensitizer in squamous cell carcinoma of cervix. 7 Factors like broad clinical effectiveness and low toxicity profile among different malignancies advocates its use in cervical tumors treatment. Capecitabine is an oral 5-FU pro-drug; it is converted to 5-FU by enzyme thymidine phosphorylase (TP).…”

Section: Introductionmentioning

confidence: 99%

Concomitant Chemo-Radiotherapy with Oral Capecitabine in Locally Advanced Squamous Cell Carcinoma Cervix

Bashir¹,

Mehreen²,

Anis³

et al. 2022

PJMHS

View full text Add to dashboard Cite

Background: Cervical carcinoma is the fourth most common malignant neoplasm after carcinoma of the breast, lung, colorectal, endometrium and ovary. Aim: To assess the all RECIST responses of concomitant chemo-radiotherapy with capecitabine in locally advanced squamous cell carcinoma cervix in a tertiary healthcare facility at Multan. Methodology: It was a Descriptive case series Conducted at the Department of Clinical Oncology, Nishtar Hospital Multan. Patients (n=60) with locally advanced squamous cell carcinoma cervix received conventional radiation (Total Dose: 45Gy) with 825 mg/m2 twice daily Capecitabine for five days a week for 6 weeks and followed by brachytherapy. Data was evaluated by using SPSS version 23. Post stratification Chi-square test was applied with P-value of 0.05 was considered as significant. Results: Mean age of patient population was 39.5±6.8 (range: 31-52) years. Majority i.e. 30(50%) were between 30 to 40 years of age. The overall response rate was 88%, complete Response Rate was 80%, Partial Response rate was 8.3%, Stable Disease lasting ≥6 months was 5%, Progressive Disease was 6.7% in 60 patients at the end of treatment. Commonly observed performance status was ECOG 0 (n=57, 95.0%) while most of the patients had stage IIB at presentation (n= 35, 58.3%). Practical Implication: Current project helped health providers to evaluate response rate to cervical carcinoma treatment to oral capeccitabine. With other chemo-drugs like Cisplatin, renal toxicity developed even with single low dose as elderly patients are more susceptible. Because renal toxicity of oral capecitabine was low as compared to cisplatin thus it was more effective than cisplatin. Due to low local data regarding oral capecitabine in cervical carcinoma as treatment option so planned present study. Conclusion: It was concluded that patients of cervical carcinoma showed better response rate to concomitant chemo-radiation using Capecitabine with low renal toxicity. Keywords: Cervical Cancer, Oral Capecitabine, Concurrent Chemo-Radiation and Brachytherapy.

show abstract

Evaluation of Outcomes in Patients With Carcinoma of the Cervix Treated With Concurrent Radiation and Cisplatin Versus Cisplatin/5-FU Compared With Radiation Alone

Cited by 13 publications

References 18 publications

Comparison of platinum monotherapy with concurrent chemoradiation therapy versus platinum-based dual drug therapy with concurrent chemoradiation therapy for locally advanced cervical cancer: a systematic review and meta-analysis

Comparison of platinum monotherapy with concurrent chemoradiation therapy versus platinum-based dual drug therapy with concurrent chemoradiation therapy for locally advanced cervical cancer: a systematic review and meta-analysis

Opportunities for Patient Matching Algorithms to Improve Patient Care in Oncology

Concomitant Chemo-Radiotherapy with Oral Capecitabine in Locally Advanced Squamous Cell Carcinoma Cervix

Contact Info

Product

Resources

About